drugset
drugset / Trial / NCT04597450

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

NCT04597450 ↗

Phase 1 Completed 35 enrolled H. Lundbeck A/S
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.

Timeline

Start
2020-09-30
Primary completion
2023-02-13
Completion
2023-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AG06466 Unknown 30 mg Oral

Indications

post-traumatic stress disorder